Welcome to our dedicated page for Lexaria Bioscien news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscien stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) regularly issues news updates that focus on the development and evaluation of its patented DehydraTECH™ oral drug delivery platform. Company press releases highlight progress in human and animal studies, capital raising activities, strategic partnerships, and expansion of its intellectual property portfolio. For followers of LEXXW, this news flow offers insight into how DehydraTECH is being tested and positioned within the pharmaceutical landscape.
A major theme in Lexaria’s recent news is its work with GLP‑1 drugs such as semaglutide, tirzepatide, and liraglutide. The company reports results from multiple human pilot studies and a Phase 1b study in Australia (GLP‑1‑H24‑4), where DehydraTECH‑processed oral formulations are compared against established injectable or oral products. These releases detail safety and tolerability outcomes, reductions in total and gastrointestinal adverse events, and comparative performance on measures like HbA1c, body weight, body composition, and pharmacokinetics.
News items also cover exploratory findings with DehydraTECH‑CBD, including reported blood pressure reductions in a clinical study arm, and pre-clinical work such as a fluorescently tagged semaglutide rodent biodistribution study. Beyond R&D, Lexaria’s announcements describe registered direct offerings on Nasdaq, concurrent warrant placements, and the intended use of proceeds to fund research, working capital, and general corporate purposes.
Additional updates include the extension of a Material Transfer Agreement with a pharmaceutical company to evaluate DehydraTECH, the engagement of a global life science business development advisory firm, and the issuance of new patents in areas such as diabetes, epilepsy, and antiviral treatments. Investors and observers monitoring LEXXW news can use these releases to track Lexaria’s clinical progress, partnering discussions, financing activities, and the evolution of its DehydraTECH-focused strategy over time.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced promising results from its oral nicotine absorption study NIC-A21-1, showcasing its DehydraTECH technology. The study indicated that DehydraTECH-nicotine reached blood plasma levels 10 to 20 times faster than control methods, achieving peak levels up to 10 times higher. The technology was designed to improve nicotine delivery via oral pouches, aiming to provide a safer alternative for smokers. A larger human study is planned to further validate results against leading brands in the growing nicotine oral pouch market, projected to reach $21.8 billion by 2027.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) will be featured at the 23rd Annual H.C. Wainwright Global Investment Conference from September 13-15, 2021. CEO Chris Bunka will share the latest company updates starting September 13 at 7:00 AM ET. Attendees can register on the conference website. Lexaria's patented DehydraTECH technology enhances drug absorption and is also evaluated for various pharmaceutical applications. The company holds 21 patents and 50 pending worldwide, demonstrating strong intellectual property.
Lexaria Bioscience Corp. has initiated the process for an Investigational New Drug (IND) application with the FDA for its DehydraTECH-CBD formulation aimed at treating hypertension. This decision follows successful results from multiple studies demonstrating the formulation's bioabsorption and effectiveness in reducing blood pressure without significant side effects. Lexaria is working with a consultancy for regulatory compliance and plans to leverage upcoming clinical studies to bolster its application. The hypertension market is valued at approximately $28 billion and presents significant growth potential.
Lexaria Bioscience Corp. (LEXX, LEXXW) released promising initial results from its human clinical study HYPER-H21-2, showing a significant 23% decrease in blood pressure (BP) with DehydraTECH-CBD compared to placebo. Over 24 hours, volunteers experienced an average 20 mmHg reduction in BP and a notable 7.0% decrease in systolic pressure (p < 0.001). The study indicates DehydraTECH-CBD's potential as a tolerable treatment for hypertension, with no serious side effects reported. Further data analyses are ongoing, and Lexaria plans to conduct additional studies to explore long-term effects.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) released partial results from the human clinical study HYPER-H21-1, showing that DehydraTECH-CBD significantly reduces blood pressure in hypertensive patients. The study, involving 24 volunteers aged 45-65, reported up to a 13 mmHg reduction in systolic blood pressure within 50 minutes of administration. No serious side effects were observed, unlike the control group using generic CBD. Lexaria plans further analyses and continued research to enhance efficacy through repeat dosing.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announces significant growth as its DehydraTECHTM technology is now utilized by brands in over 7,000 stores across the US. CEO Chris Bunka highlights the technology's role in boosting market share and sales for clients like Cannadips and New World CBD. The company plans to introduce five new products powered by DehydraTECH in Q4 2021. Lexaria's tech increases bio-absorption significantly and reduces onset time for cannabinoids and other compounds, with ongoing research and licensing efforts enhancing its market position.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) completed dosing in its second human clinical study, HYPER-H21-2, involving 16 participants assessing the effects of DehydraTECH 2.0-enabled CBD on blood pressure. The study, fully funded by company resources, included continuous monitoring and aims to provide insights into potential blood pressure reduction. Preliminary results are expected in September. Additionally, Lexaria received a second patent in Japan, expanding its intellectual property portfolio to 21 patents granted, enhancing its competitive edge in drug delivery technology.
Lexaria Bioscience Corp. announced it received US$3,817,643 from the exercise of warrants linked to its January 2021 public offering. A total of 580,189 shares were issued at an exercise price of US$6.58 per share. The funds will support its ongoing research programs and general corporate needs, with sufficient capital to sustain operations well into 2022. Lexaria's DehydraTECH technology enhances drug absorption and is licensed to various companies, including a major tobacco firm.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the successful achievement of all objectives in its 2021 antiviral drug program. The company tested five compounds from three antiviral drug classes, achieving up to a three-fold increase in oral drug absorption with its DehydraTECH technology. The results showed significant improvements in bioavailability for drugs like Colchicine and Remdesivir. Next steps include larger efficacy evaluations in infected animals and pursuing collaborations for further product development.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced positive results from its study VIRAL-A20-3, demonstrating that its DehydraTECH technology significantly enhances the delivery of colchicine, a drug with potential anti-inflammatory effects useful in treating SARS-CoV-2/COVID-19 symptoms. The study showed a 91% improvement in peak concentration and a 167% increase in total drug delivery compared to control. The findings suggest potential for improved bioavailability of colchicine, which may allow for lower dosing and enhanced therapeutic effects.